Workflow
Cannabis
icon
Search documents
CBD Life Sciences Inc. (CBDL) Announces LOI With New Jersey Dispensary, Unlocking New Revenue Channels & Strategic Growth Opportunities
Accessnewswire· 2025-09-23 11:00
Strategic collaboration expands CBDL's footprint in the booming East Coast cannabis market projected to surpass $33 billion by 2030, while strengthening retail distribution and cross-brand synergies SCOTTSDALE, AZ / ACCESS Newswire / September 23, 2025 / CBD Life Sciences Inc. (OTC:CBDL), through its wholly owned subsidiary, CBD Vault, is proud to announce that it has entered into a Letter of Intent (LOI) with a licensed dispensary in New Jersey. This powerful agreement represents not just product placement ...
Jushi Holdings Inc. Announces Favorable Modifications to Existing Manassas, VA Mortgage
Globenewswire· 2025-09-22 12:20
Core Viewpoint - Jushi Holdings Inc. has successfully modified its existing secured commercial loan, receiving an additional $4 million, extending the maturity date to September 18, 2030, and lowering the interest rate floor from 8.25% to 7.50%, which will enhance its balance sheet for growth initiatives [1]. Group 1: Loan Modification Details - The company received an additional $4,000,000 in loan proceeds [1] - The maturity date of the loan has been extended to September 18, 2030 [1] - The interest rate floor has been reduced from 8.25% to 7.50% [1] - The loan remains secured by the company's cultivation and manufacturing facility in Manassas, Virginia [1] Group 2: Use of Funds - The additional loan proceeds will be allocated for capital expenditures, working capital, and other corporate purposes [1]. Group 3: Company Overview - Jushi Holdings Inc. is a vertically integrated cannabis company focused on building a multi-state portfolio of branded cannabis assets through acquisitions and competitive applications [2]. - The company aims to maximize shareholder value while delivering high-quality products across the cannabis ecosystem [2].
X @Forbes
Forbes· 2025-09-22 05:30
WATCH: How Cheech & Chong Turned Their Legacy Into A $100 Million Cannabis Empire https://t.co/jVAA4TT8vf https://t.co/tq1cay4owV ...
Cannabis Firm Flora Wins $401M Deal at $3B Valuation for 0G
FinanceFeeds· 2025-09-21 20:06
Core Viewpoint - Flora Growth is transforming from a cannabis company to a player in the blockchain and AI sectors, announcing a $401 million treasury initiative to support the Zero Gravity (0G) blockchain project [1][4]. Financial Details - The deal consists of $35 million in cash and $366 million in digital assets, primarily in 0G tokens, with participation from various firms including DeFi Development Corp. and Hexstone Capital [2][3]. - Flora Growth's treasury will also include Solana (SOL) tokens, enhancing its connection to the Solana ecosystem [2]. Strategic Implications - The incoming CEO described the treasury move as a means to provide institutional investors with equity-based exposure to a transparent and privacy-first AI infrastructure [6]. - The pivot to blockchain and AI reflects a broader trend of companies in struggling industries rebranding to attract capital [13]. Market Reaction - Following the announcement, Flora Growth's shares surged 69% in after-hours trading, reversing a year-to-date decline of 32%, indicating strong investor interest in crypto-AI narratives [8]. Technological Aspirations - Zero Gravity Labs claims to have developed a distributed AI training technology that has achieved a 357x efficiency gain over traditional frameworks, positioning it competitively against major tech firms [5]. Future Prospects - The 0G Foundation plans to airdrop tokens to early supporters, with a projected fully diluted valuation of about $3 billion at a $3 token price, aligning it with other notable projects [7]. - The success of Flora Growth's pivot will depend on the real-world performance of 0G's AI technology and the anticipated exchange listings [12][14].
Top Marijuana Stocks to Watch as Federal Reform Advances
Marijuana Stocks | Cannabis Investments And News. Roots Of A Budding Industry.™· 2025-09-21 14:00
Industry Overview - The U.S. cannabis industry generated over $33 billion in sales during 2024, making it one of the fastest-growing consumer sectors, with projections of annual sales surpassing $56 billion by 2030 [1] - Federal rescheduling efforts could ease tax burdens for cannabis companies, while more states are preparing adult-use legalization measures, increasing growth opportunities for multi-state operators [1][5] - The sector is characterized by volatility, necessitating careful evaluation of fundamentals and sector catalysts [1][12] Company Highlights Green Thumb Industries (OTC: GTBIF) - Green Thumb Industries operates over 100 dispensaries across 14 states, focusing on high-demand, limited-license markets, and has confirmed 108 locations with steady growth [3][5] - The company reported quarterly revenue of approximately $293 million in 2025, reflecting a year-over-year increase, with adjusted EBITDA around $83 million and operating cash flow of $56 million [4][5] - Green Thumb has a balance sheet with $177 million in cash, allowing for financial flexibility and continued investment [5] Glass House Brands (OTC: GLASF) - Glass House Brands focuses on California, managing 10 dispensaries and emphasizing large-scale greenhouse cultivation and efficient production [6][8] - The company reported second-quarter revenue of $59.9 million, an 11% year-over-year increase, with gross margins expanding to 53% and adjusted EBITDA of $18.1 million [8] - Cash reserves stood at $44.2 million, and cultivation volume reached 231,000 pounds during the quarter, with costs averaging $91 per pound [8] Cresco Labs (OTC: CRLBF) - Cresco Labs operates 71 Sunnyside dispensaries and focuses on both retail and wholesale, with significant brand development across various product categories [9][10] - The company posted revenue of $164 million in the second quarter of 2025, with an adjusted gross margin of 50.6% and adjusted EBITDA of approximately $41 million [11] - Cresco reported a net loss of $14 million, primarily from non-cash impairments, but has effectively controlled expenses, with selling, general, and administrative expenses at 31% of revenue [11] Investment Considerations - Investors are encouraged to apply technical analysis, monitoring support, resistance, and moving averages to improve timing in this volatile sector [12] - The upcoming catalysts, such as federal rescheduling and new state launches, make these three stocks—Green Thumb, Glass House, and Cresco—worth watching closely [12]
X @Forbes
Forbes· 2025-09-19 07:30
B2B Cannabis Platform LeafLink Names Ex-Lyft Exec As CEO https://t.co/eoe7gb1Efs https://t.co/kAMvsemgbI ...
Best Cannabis Stocks in Canada to Watch Now: Technical Signals and Market Outlook
Marijuana Stocks | Cannabis Investments And News. Roots Of A Budding Industry.™· 2025-09-18 14:00
Industry Overview - The Canadian cannabis sector is a focal point for investors as it continues to evolve with expanding operations and long-term growth strategies [1][3] - The U.S. cannabis industry has surpassed $33 billion in annual sales, with projections exceeding $50 billion by 2030, indicating significant global opportunities for Canadian companies [1] - Recent developments in U.S. legalization discussions, including potential federal rescheduling of cannabis, could enhance banking access and reduce tax burdens, fostering optimism for both U.S. and Canadian firms [1][2] Company Summaries Cronos Group (CRON) - Cronos Group focuses on research, development, and global distribution, emphasizing branded products and international medical cannabis opportunities rather than a large U.S. dispensary network [4][7] - The company reported revenue of approximately CAD $33.5 million, a 20% year-over-year increase, but also a net loss of about CAD $38.5 million due to foreign-exchange headwinds and investment costs [7] - Cronos has improved gross margins and maintains a strong liquidity position, allowing for strategic flexibility and potential growth in global medical markets [7] SNDL Inc. (SNDL) - SNDL has established one of the largest retail footprints in Canada, operating over 180 retail locations under various banners, while also pursuing investments in the U.S. market [8][10] - The company reported net revenue of approximately CAD $244.8 million, with a gross profit increase of over 16% and positive operating income of around CAD $5 million for the first time in several years [10] - SNDL's strong cash position of over CAD $200 million and no debt on its balance sheet provide financial stability, while its strategy focuses on expanding its retail network and preparing for cross-border opportunities [10] Aurora Cannabis (ACB) - Aurora Cannabis emphasizes medical cannabis exports and global distribution, serving regulated medical markets in Europe and Australia, while shifting away from low-margin recreational cannabis [11][13] - The company reported total net revenue of about CAD $81 million, reflecting nearly 30% growth year-over-year, with medical cannabis sales increasing over 40% to more than CAD $61 million [13] - Aurora's adjusted gross margins improved to roughly 54%, showcasing higher profitability from its medical and international operations, despite challenges from regulatory shifts and competition [13] Investment Considerations - Investors should monitor the financial performance, operational strategies, and regulatory changes affecting Cronos Group, SNDL, and Aurora Cannabis, as each company presents unique opportunities and risks in the evolving cannabis landscape [14]
Tilray stock price sits and waits for Trump cannabis rescheduling
Invezz· 2025-09-17 15:02
Core Viewpoint - Tilray Brands stock has experienced a significant bullish rebound, increasing from a low of $0.352 in June to $1.25, representing a 256% rise [1] Company Summary - The stock price movement indicates strong market interest and potential investor confidence in Tilray Brands [1] - The increase in stock price suggests a positive sentiment surrounding the company's future prospects [1] Market Expectations - Market participants are closely monitoring developments as they anticipate further movements in Tilray Brands stock [1] - The current price level may indicate a pivotal point for future trading activity and investment decisions [1]
Green Thumb Launches $50M Buyback: Time to Get Bullish on the Stock?
ZACKS· 2025-09-17 13:56
Group 1 - Green Thumb Industries (GTBIF) announced a $50 million share repurchase program, leading to a 9% increase in its stock price [1][12] - The buyback program is a significant move in the cannabis industry, where such actions are uncommon due to capital constraints and regulatory challenges, indicating management's confidence in the company's long-term prospects [2][12] - Previous buyback efforts in 2023 saw the company repurchase nearly 13.5 million shares for $108 million, demonstrating a consistent approach to returning value to shareholders [4][12] Group 2 - Green Thumb's revenue for Q2 2025 increased nearly 5% year-over-year to $293 million, with the consumer packaged goods segment growing over 8%, but retail sales growth was flat due to price compression [8] - The company's gross profit margin fell to 49.9%, down 380 basis points from the previous year, while selling and operating expenses rose by 11%, contributing to a net loss for the quarter [9] - The company faces ongoing pricing pressures and competition in the saturated U.S. cannabis market, which may hinder profitability without regulatory reform or improved retail pricing dynamics [10][13] Group 3 - Green Thumb operates solely in the U.S. market, making it vulnerable to domestic regulatory risks and competition from peers like Curaleaf and Tilray, which are expanding internationally [7][14] - Year-to-date, GTBIF shares have declined nearly 6%, contrasting with a 5% growth in the broader industry [15] - EPS estimates for 2025 and 2026 have been revised downward over the past 60 days, reflecting concerns about the company's financial outlook [17]
High Tide Q3: Stock May Drop Further To Offer Better Entry Points
Seeking Alpha· 2025-09-17 12:30
Financial Performance - High Tide Inc. reported record-high revenues, gross profit, and free cash flow for Q2-2025, marking it as the best quarter in the company's history [1] Market Expansion - High Tide has officially entered the German medical cannabis market, indicating a strategic expansion into new territories [1]